Legend Biotech (LEGN) Cash from Operations (2019 - 2025)
Legend Biotech (LEGN) posted Cash from Operations of 12200000.0 for Q4 2025, down 142.36% on a QoQ basis from 28801000.0 in Q3 2025, and up 85.14% year-over-year from 6589605.26 in Q4 2024.
Legend Biotech (LEGN) has 7 years of Cash from Operations data on file, last reported at 12200000.0 in Q4 2025.
- In Q4 2025, Cash from Operations rose 85.14% year-over-year to 12200000.0; the TTM figure through Dec 2025 stood at 100195000.0 (up 30.45% YoY), while the FY2025 annual figure was 100200000.0, up 30.42% from the prior year.
- Cash from Operations eased to 12200000.0 in Q4 2025, from 28801000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 28801000.0 in Q3 2025 and bottomed at 198465000.0 in Q4 2021.
- A 5-year average of 58313050.0 and a median of 59228500.0 in 2021 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 13084.86% — and 2025, when it jumped 137.99%.
- Year by year, Cash from Operations stood at 198465000.0 in 2021, then soared by 74.94% to 49742000.0 in 2022, then sank by 92.28% to 95645000.0 in 2023, then gained by 14.16% to 82100000.0 in 2024, then soared by 85.14% to 12200000.0 in 2025.
- The last three Cash from Operations figures came in at 12200000.0 (Q4 2025), 28801000.0 (Q3 2025), and 13042000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -354.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.20 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Sep 30, 2025 | 28.80 Mn |
| Sep 30, 2025 | 28.80 Mn |
| Jun 30, 2025 | -13.04 Mn |
| Jun 30, 2025 | -13.04 Mn |
| Mar 31, 2025 | -103.75 Mn |
| Mar 31, 2025 | -103.75 Mn |
| Dec 31, 2024 | -82.10 Mn |
| Dec 31, 2024 | -82.10 Mn |
| Sep 30, 2024 | -75.82 Mn |
| Sep 30, 2024 | -75.82 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | 15.52 Mn |
| Mar 31, 2024 | 15.52 Mn |
| Dec 31, 2023 | -95.65 Mn |
| Dec 31, 2023 | -95.65 Mn |
| Sep 30, 2023 | -60.85 Mn |
| Sep 30, 2023 | -60.85 Mn |
| Jun 30, 2023 | -97.57 Mn |
| Jun 30, 2023 | -97.57 Mn |
| Mar 31, 2023 | -139.22 Mn |
| Mar 31, 2023 | -139.22 Mn |
| Dec 31, 2022 | -49.74 Mn |
| Dec 31, 2022 | -49.74 Mn |
| Sep 30, 2022 | -72.11 Mn |
| Sep 30, 2022 | -72.11 Mn |
| Jun 30, 2022 | -740,000.00 |
| Jun 30, 2022 | -740,000.00 |
| Mar 31, 2022 | -78.69 Mn |
| Mar 31, 2022 | -78.69 Mn |
| Dec 31, 2021 | -198.47 Mn |
| Dec 31, 2021 | -198.47 Mn |
| Sep 30, 2021 | -44.59 Mn |
| Sep 30, 2021 | -44.59 Mn |
| Jun 30, 2021 | -57.61 Mn |
| Jun 30, 2021 | -57.61 Mn |
| Mar 31, 2021 | -26.79 Mn |
| Mar 31, 2021 | -26.79 Mn |
| Dec 31, 2020 | -223.01 Mn |
| Dec 31, 2020 | -223.01 Mn |
| Sep 30, 2020 | -64.38 Mn |
| Sep 30, 2020 | -64.38 Mn |
| Jun 30, 2020 | -56.89 Mn |
| Jun 30, 2020 | -56.89 Mn |
| Mar 31, 2020 | -45.80 Mn |
| Mar 31, 2020 | -45.80 Mn |
| Dec 31, 2019 | -59.99 Mn |
| Dec 31, 2019 | -59.99 Mn |
| Sep 30, 2019 | 19.95 Mn |
| Sep 30, 2019 | 19.95 Mn |
| Jun 30, 2019 | -38.77 Mn |
| Jun 30, 2019 | -38.77 Mn |